Prognostic and predictive markers for the new immunotherapies

Area of Science:

• Immunotherapy
• Oncology
• Biomarker Discovery

Background:

• Monoclonal antibodies targeting the programmed cell death 1 (PD-1) pathway demonstrate significant antitumor activity with improved toxicity profiles compared to older immunotherapies.
• Agents like pembrolizumab, nivolumab, and MPDL3280A (anti-PD-1 and anti-PD-L1 antibodies) have received accelerated approval or breakthrough designation for various advanced cancers, including melanoma, Hodgkin lymphoma, and bladder cancer.
• These therapies are also showing efficacy in previously non-immune-responsive tumors like non-small-cell lung cancer and head and neck cancer.

Purpose of the Study:

• To review the emerging role of programmed cell death 1 ligand (PD-L1) as a predictive biomarker for PD-1-directed cancer immunotherapies.
• To highlight the current challenges in PD-L1 assay standardization and validation.
• To emphasize the need for additional biomarkers to optimize patient selection for PD-1-based combination therapies.

Main Methods:

• Review of clinical trial data and FDA designations for anti-PD-1/PD-L1 therapies.
• Analysis of the current landscape of PD-L1 companion diagnostics.
• Discussion of the limitations of PD-L1 expression as a sole predictive biomarker.

Main Results:

• PD-1 pathway blockade is effective across multiple cancer types, including those not traditionally considered immunogenic.
• Multiple assays exist to detect PD-L1 expression, but they lack standardization and prospective validation.
• Tumor cell PD-L1 expression shows limited predictive value for combination therapies, suggesting a need for broader biomarker strategies.

Conclusions:

• PD-1 pathway inhibitors represent a significant advancement in cancer immunotherapy.
• Standardization and validation of PD-L1 assays are critical for reliable patient stratification.
• Developing novel predictive biomarkers is essential for maximizing the benefit of PD-1-based combination treatments in oncology.